The Pipeline4 Nov 2018 13:44
Immunobody
SCIB1 ... adjuvant melanoma HLA restricted 45% of patients
SCIB1 combination resected Melanoma HLA restricted 45% of Patients
SCIB1 mark two 90% of patients possible used with nanovesicle if SCIB2 is successful
SCIB2 combination Lung cancer to start ... 90% of patients as its based on Mark 2 technology fully funded to stage 2 results, possible increase in target cancers (covered by CRUK)
oesophageal,ovarian, bladder and prostate cancers, as well as neuroblastoma, melanoma and sarcoma.
Nottingham Trent University and the University of Portsmouth have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme (GBM)
Trent have also done a lot of work on the Pap protein for prostate cancer
The work focused on the prostatic acid phosphatase (PAP) protein, which is present in more than 90% of prostate tumours. Scientists were able to develop a new prostate cancer vaccination strategy utilising a portion, or 'epitope' of this PAP protein - PAP 114 - which was capable of preventing and reducing tumour growth in pre-clinical trials.
That Group alone would keep a Big Pharma busy
Moditope ....
Not sure how to describe it now, as so many components of it are starting to appear as interactive and indeed as a whole package treatment for late stage. How this all comes together is part of this Modi 3 Grand Challenge program of forming templates around patients own tumours which allows sequenced treatments and combinations for max effect. So the pipeline has moved to "Cancer" think about that eh !
Sign In
Follow the stocks
